Intensity Therapeutics’ INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology
INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer Data was generated…